Summary
The blood pressure lowering capacity of felodipine administered either as extended release tablets once or twice daily or as plain tablets twice daily has been compared in a double-blind, three-way cross-over study in 16 hypertensive patients. All the patients were on long-term treatment with 10 or 20 mg felodipine daily and other antihypertensive therapy (mainly beta-blockers) was allowed if it was kept unchanged. Non-invasive blood pressure and heart rate recordings were obtained throughout 24 hour periods using an Accutracker ambulatory system.
The 24 h mean systolic and diastolic blood pressures after extended release tablets o.m. did not differ significantly from those after extended release tablets b.d. or plain tablets b.d. There was a tendency for the extended release tablets given o.m. to reduce blood pressure somewhat more in the morning, and for the extended release tablets b.d. to reduce blood pressure more during the night than the other treatments. Mean 24 h heart rate after all treatments was comparable. Manual recordings confirmed these results. Blood pressure was well-controlled throughout the 24 h period by all three treatments.
The extended release tablets tended to give less extreme plasma concentrations of felodipine. This may be of value for patients with adverse vasodilator effects. For a majority of hypertensive patients the adequacy of blood pressure control and the simplicity of once daily dosing will favour the extended release tablet given once daily.
Similar content being viewed by others
References
Betaloc® Compliance Canadian Cooperative Study Group (1984) A study of efficacy, tolerance and compliance of once-daily versus twice-daily metoprolol (Betaloc®) in hypertension. Clin Invest Med 7: 95–102
Saltiel E, Ellrodt AG, Monk JP, Langley MS (1988) Felodipine: A review of its pharmacokinetic and pharmacodynamic properties, and therapeutic use in hypertension. Drugs 36: 387–428
Blychert E, Hedner T, Dahlöf C, Elmfeldt D (1990) Plasma concentration effect relationships of intravenous and extended release oral felodipine in hypertensive patients. J Cardiovasc Pharmacol 15: 428–435
Liedholm H, Melander A (1989) A placebo-controlled dose-response study of felodipine extended release in hypertensive patients. J Cardiovasc Pharmacol 14: 109–113
Campbell LM, Ross JRM, Goves JR, Lees CTW, McCullagh A, Barnes P, Timerick SJB, Richardson PDI (1989) A dose-finding placebo-controlled study of felodipine-ER once daily in the treatment of hypertension. J Cardiovasc Pharmacol 14: 869–873
Hart W, Westberg B (1990) Felodipine extended-release tablets once daily equivalent to plain tablets twice daily in hypertension. J Cardiovasc Pharmacol 15: (Suppl 4): S65-S69
Blychert E, Wingstrand K, Edgar E, Lidman K (1990) Plasma concentration profiles and antihypertensive effect of conventional and extended-release felodipine tablets. Br J Clin Pharmacol 29: 39–45
Ahnoff M (1984) Determination of felodipine in plasma by capillary gas chromatography with electron capture detection. J Pharm Biomed Analysis 2: 519–526
Collste P, Danielson M, Elmfeldt D et al (1985) Long term experience of felodipine combined with beta-blockade and diuretics in refractory hypertension. Drugs 29 [Suppl 2]: 124–130
The Swedish Multicentre Group (1986) Can standard triple treatment of hypertension be replaced by the combination of felodipine and a beta-blocker? J Hypertens 4 [Suppl 5]: 446–447
Author information
Authors and Affiliations
Additional information
This study was supported by a grant from the Swedish Heart and Lung Foundation
Rights and permissions
About this article
Cite this article
Blychert, E., Frisén, M., Karlsson, Ö. et al. Twenty-four hour blood pressure profiles in hypertensive patients following various formulations and dosage regimens of felodipine. Eur J Clin Pharmacol 42, 25–30 (1992). https://doi.org/10.1007/BF00314915
Issue Date:
DOI: https://doi.org/10.1007/BF00314915